On April 8, 2022 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and collaboration partner Redx Pharma (AIM: REDX) reported data showing the pan-RAF kinase inhibitor, JZP815, was active in multiple RAF- and RAS-mutant tumor pre-clinical models, with a pharmacokinetic profile that may provide drug exposure required for target engagement in humans (Press release, Jazz Pharmaceuticals, APR 8, 2022, View Source [SID1234611792]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As a precision pan-RAF inhibitor with a differentiated mechanism of action, JZP815 is a promising drug candidate for several types of difficult-to-treat solid tumors, including colorectal cancer, non-small cell lung cancer, melanoma and ovarian cancer," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. "By not inducing paradoxical pathway activation, which can stimulate the growth of certain cancers, JZP815 may offer a significant advancement in the pan-RAF inhibitor class with the potential to address unmet patient need. We look forward to submitting the investigational new drug application for JZP815 this year."
JZP815 targets specific components of the mitogen-activated protein kinase (MAPK) pathway, namely all three RAF proteins – ARAF, BRAF and CRAF – that when activated by oncogenic mutations, can be a frequent driver of human cancer.
Pre-clinical data of JZP815 administered orally as both a monotherapy and in combination with mitogen-activated protein kinase (MAPK) pathway inhibitors were presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting (AACR) (Free AACR Whitepaper). Key findings of several pre-clinical models include1:
JZP815 inhibited all 3 RAF kinase family members (ARAF, BRAF, CRAF) at low-to-sub nanomolar potencies in biochemical assays.
JZP815 did not induce significant paradoxical pathway activation, observed with approved first generation BRAF-selective inhibitors, while demonstrating equivalent cellular potencies for MAPK pathway inhibition driven by either mutant RAF monomers or dimers or mutant RAS-induced RAF dimers in tumor cells.
JZP815 significantly inhibited tumor growth, including inducing tumor regression, as a single agent in multiple mouse xenograft solid tumor models harboring RAS and/or BRAF mutations.
JZP815’s pharmacokinetic profile sustained on-target pathway pharmacodynamic responses in a predictable dose and time dependent manner.
JZP815 demonstrated enhanced activity when combined with inhibitors of other MAPK pathway components including MEK1/2, SOS1, SHP2 and EGFR inhibitors in both class 2 and class 3 mutant BRAF patient-derived tumor cells ex vivo, and KRAS mutant NSCLC and colorectal cancer xenografts in vivo.
The full Jazz presentation abstract, titled, "JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS mutant tumor pre-clinical models" is available at View Source!/10517/presentation/15283.
Jazz acquired JZP815 from Redx Pharma, and the two companies are collaborating on this pre-clinical research. Jazz plans to submit an IND for JZP815 this year.
About JZP815
JZP815 is an investigational, pre-clinical stage pan-RAF kinase inhibitor that was discovered and developed using state-of-the-art screening methodologies and medicinal chemistry. JZP815 targets specific components of the mitogen-activated protein kinase (MAPK) pathway that, when activated by oncogenic mutations, can be a frequent driver of human cancer. JZP815 potently inhibits both monomer- and dimer-driven RAF signaling (e.g., RAS-induced), prevents paradoxical pathway activation induced by BRAF selective inhibition, and is active against class 1, class 2, and class 3 BRAF mutants, as well as BRAF fusions and CRAF mutants. JZP815 is not currently approved for use anywhere in the world. JZP815 is part of Jazz’s growing early-stage R&D pipeline focused on precision oncology in solid tumors.